CurrentRheuma — Across rheumatic diseases

Cluster analysis identifies anti‐synthetase syndrome as a distinct and heterogeneous clinical entity: Analysis from the Classification Criteria for Anti‐Synthetase Syndrome project database

2026-11-12T11:15:54.044Z

Research article · Arthritis Rheumatol, 2026.

Pneumocystis jirovecii pneumonia prophylaxis in rare systemic autoimmune rheumatic diseases: a systematic review of randomised controlled trials within the European Reference Network on Connective Tissue and Musculoskeletal Diseases

2026-11-10T18:15:33.627Z

Meta-analysis · Clin Exp Rheumatol, 2026.

Perceptions of Rheumatologists on Barriers and Enablers to Adoption of Interdisciplinary Models of Care in Rheumatology in Ontario, Canada

2026-11-09T16:15:46.851Z

Research article · Arthritis Care Res (Hoboken), 2026.

Global burden and economic cost of musculoskeletal disorders in the working-age population, 1990-2023

2026-11-05T16:08:02.128Z

Secondary analysis · Ann Rheum Dis, 2026.

All-cause and cause-specific mortality in people with rare autoimmune rheumatic diseases in England using whole population data

2026-11-05T13:24:18.717Z

Cohort study · Rheumatology (Oxford), 2026.

Combination advanced therapy use and infection risks in immune-mediated inflammatory diseases

2026-11-05T13:24:18.717Z

Cohort study · Rheumatology (Oxford), 2026.

Comorbidity management in inflammatory rheumatic diseases: a dual-perspective survey of patients and rheumatologists

2026-11-05T13:24:18.717Z

Cross-sectional study · Arthritis Res Ther, 2026.

Prevalence of Rheumatoid Arthritis, Osteoarthritis and Gout among Alaska Native/American Indian Peoples in Alaska

2026-11-05T13:24:18.717Z

Research article · J Rheumatol, 2026.

Synovial fluid cell isolation protocol affects immune cell recovery and composition across inflammatory states

2026-11-05T13:24:18.717Z

Research article · RMD Open, 2026.

Cardioprotective mechanisms and efficacy of colchicine, methotrexate, hydroxychloroquine, sulfasalazine and leflunomide in inflammatory rheumatic and musculoskeletal diseases

2026-11-05T13:10:58.883Z

Research article · Rheumatology (Oxford), 2026.

Health and Economic Outcomes Associated With Musculoskeletal Disorders Attributable to High Body Mass Index in 192 Countries and Territories in 2019

2026-11-04T23:58:57.553Z

Cross-sectional study · JAMA Netw Open, 2023. Musculoskeletal disorders attributable to high BMI, 2019: Prevalent cases of LBP attributable to high BMI 36.3 million (UI, 18.4-61.0 million)

Possible relationship between hydroxychloroquine and electrocardiographic and echocardiographic abnormalities in patients with inflammatory rheumatic diseases––a monocentric study

2026-11-04T23:48:14.847Z

Cross-sectional study · Lupus, 2023. Predictors of echocardiography changes — HCQ cumulative dose: OR 1.001 (95% CI 1.000-1.002); p = .033; not a predictor when adjusted for age

Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Remission/low disease activity, ADA bio-originator to SB5, 4 months (T4): Baseline 92.7% · T4 80.9%

ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

2026-11-04T23:43:54.165Z

Guideline or statement · Clin Exp Rheumatol, 2023.

Long-term evaluation of pulmonary function and survival of patients with interstitial pneumonia with autoimmune features

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2021. FVC%, DLCO% and six-minute walk distance over time: FVC%, DLCO%, and SMWD remained stable over time

Medical cannabis use by rheumatology patients in routine clinical care: results from The Ontario Best Practices Research Initiative

2026-11-04T23:43:54.165Z

Cross-sectional study · Clin Exp Rheumatol, 2022. Medical cannabis use (current or within <2 years): Current/past-users 163 (20.4%)

Reactogenicity, safety and disease flares following BNT162b2 mRNA COVID-19 vaccine in patients with chronic immune-inflammatory arthritis treated with biological and targeted synthetic disease-modifying anti-rheumatic drugs

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Reactogenicity, safety and flares: Frequency and severity of systemic events similar to that reported in the general population; no particular safety concerns

Antibody response in patients with autoimmune inflammatory rheumatic disease after pneumococcal polysaccharide prime vaccination or revaccination

2026-11-04T23:40:51.898Z

Cohort study · Scand J Rheumatol, 2022. Protective antibody level after vaccination, 3 months — No previous PPV23 vs PPV23 <5 years ago; p = 0.005; significantly more achieved protective level without previous PPV23; multivariable logistic regression

Construct validity of the PROMIS PF-10 in patients with inflammatory rheumatic diseases and severe limitations in physical functioning

2026-11-04T23:40:51.898Z

Cross-sectional study · Scand J Rheumatol, 2023. Correlations of PROMIS PF-10 with other measures: Strong correlation with HAQ-DI, BASFI and EQ-5D-5L index score r > 0.6

Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial

2026-11-04T23:40:51.898Z

Randomized controlled trial · Scand J Rheumatol, 2023. ≥ 50% biologic reduction, 18 months: Tapering 35 (37%) · Control 1 (2%)

Health-related quality of life in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis, results from a cross-sectional survey in Western Sweden

2026-11-04T23:40:51.898Z

Cross-sectional study · Scand J Rheumatol, 2023. PCS range across all diagnoses 39.7-41.2

Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial

2026-11-04T23:40:51.898Z

Randomized controlled trial · Scand J Rheumatol, 2022. MDA maintained, 6 months: Intervention 47 (63%) · Control 56 (74%)

Presence of SARS-CoV-2 antibodies in patients with COVID-19 like symptoms from the IENIMINI cohort

2026-11-04T23:40:51.898Z

Cohort study · Scand J Rheumatol, 2022. SARS-CoV-2 antibody positive: IMIDT with imed 57 (28.2%) · IMIDT without imed 48 (29.4%) · Control 69 (35.0%)

Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents

2026-11-04T23:40:51.898Z

Cross-sectional study · Scand J Rheumatol, 2022. Point prevalence, 1st of January 2017: PsA 0.46% · axSpA 0.41% · RA 0.78%

B Cell Reconstitution is Associated With COVID-19 Booster Vaccine Responsiveness in Patients Previously Seronegative Treated With Rituximab

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2022. Seroconversion following booster: Seroconverted following a booster 68%

Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients With Systemic Autoimmune Rheumatic Diseases on Immunomodulatory Medications

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2023. Breakthrough infection: BNT162b2 446 · mRNA-1273 329

Physical Activity Habits Among Older Adults Living With Rheumatic Disease

2026-11-04T23:37:51.551Z

Cross-sectional study · J Rheumatol, 2023. Self-reported PA level: High PA 457 (13.6%) · Moderate PA 1820 (54.4%)

Preferences for COVID-19 Vaccination in People With Chronic Immune-Mediated Inflammatory Diseases

2026-11-04T23:37:51.551Z

Cross-sectional study · J Rheumatol, 2023. Relative importance of vaccine attributes: Vaccine effectiveness (most important) 66%

Association of vocational interventions and work-related factors with disease and work outcomes in people with RMDs: A systematic review

2026-11-04T23:02:07.938Z

Meta-analysis · Semin Arthritis Rheum, 2022. Most observational studies evaluated association of work-related factors with work outcomes; limited information on impact of work on clinical outcomes

Causal association of leisure sedentary behavior with arthritis: A Mendelian randomization analysis

2026-11-04T23:02:07.938Z

Research article · Semin Arthritis Rheum, 2023. Time spent watching TV and OA (univariable MR (UVMR)): TV watching – overall OA, OR 1.80 (1.45-2.23) (95% CI)

Cognitive impairment in the immune-mediated inflammatory diseases compared with age-matched controls: Systematic review and meta-regression

2026-11-04T23:02:07.938Z

Meta-analysis · Semin Arthritis Rheum, 2022. Overall cognition — IMIDs vs Controls: SMD -0.57 (95% CI -0.70, -0.43)

Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study

2026-11-04T23:02:07.938Z

Cohort study · Semin Arthritis Rheum, 2022. Breakthrough infection by immunomodulator — Anti-CD20 monoclonal antibodies vs Antimalarial monotherapy: aHR 5.20 (95% CI 2.85, 9.48)

Perioperative treatment with TNF inhibitors does not affect survival of total hip arthroplasty in inflammatory arthritis: A registry-based cohort study

2026-11-04T23:02:07.938Z

Cohort study · Semin Arthritis Rheum, 2023. THA survival (any revision surgery), average follow-up of 5 years — TNFi vs Non-bDMARD/tsDMARD; p = 0.713; not significantly different

SARS-CoV-2 infection among patients with autoimmune rheumatic diseases; comparison between the Delta and Omicron waves in Israel

2026-11-04T23:02:07.938Z

Cohort study · Semin Arthritis Rheum, 2022. COVID-19-related hospitalization: Delta 3.9% · Omicron 1.3%

Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2)

2026-11-04T22:58:59.711Z

Research article · RMD Open, 2023. Seropositive 6 months after initial AZ vaccination: Withhold 87.5% · Continue 85.4% · Control 79.2%

Non-pharmacological interventions to promote work participation in people with rheumatic and musculoskeletal diseases: a systematic review and meta-analysis from the EULAR taskforce on healthy and sustainable work participation

2026-11-04T22:58:59.711Z

Meta-analysis · RMD Open, 2023. Work participation (quantitative synthesis, 37 RCTs; k=43 treatment comparisons); negative SMD favours intervention over comparator: SMD sick leave -0.23 (95% CI -0.33 to -0.13; k=42)

Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider

2026-11-04T22:58:59.711Z

Guideline or statement · RMD Open, 2023. Methods used to measure IFN-I pathway activation (of 412 methods): qPCR 121

Machine learning identification of thresholds to discriminate osteoarthritis and rheumatoid arthritis synovial inflammation

2026-11-04T22:57:04.788Z

Diagnostic or prognostic study · Arthritis Res Ther, 2023. Discrimination of OA vs RA, micro-AUC: Pathologist scores: micro-AUC 0.85±0.06 · Cell density: micro-AUC 0.87±0.04; optimal threshold 3400 cells/mm2; sensitivity 0.82; specificity 0.82 · Pathologist scores + cell density: micro-AUC 0.92±0.06

2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases

2026-11-04T22:50:06.138Z

Guideline or statement · Arthritis Care Res (Hoboken), 2023.

Ambulatory Medication Safety: Vaccination and Laboratory Screening for Patients Receiving Immunomodulatory Therapies

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2022. Screening at any time point: HBV screening 84.5% (2,025 of 2,396)

Assessing the Severity of COVID‐19 Lung Injury in Rheumatic Diseases Versus the General Population Using Deep Learning–Derived Chest Radiograph Scores

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2022. Maximum PXS score, 90th percentile: Rheumatic disease 90th percentile 10.2 · Comparators 90th percentile 9.2

Association Between Neighborhood Deprivation and Number of Rheumatology Providers

2026-11-04T22:50:06.138Z

Cross-sectional study · Arthritis Care Res (Hoboken), 2022. Number of rheumatologists vs ADI of practice location — First ADI quintile vs Fifth ADI quintile: ratio of rheumatologists per 100,000 people 2.1 times

Association of Area‐Level Heat and Social Vulnerability With Recurrent Hospitalizations Among Individuals With Rheumatic Conditions

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2022. ≥4 hospitalizations, 2 years post index date — Highest SVI vs Lowest SVI: aOR 1.84 (95% CI 1.43-2.36)

Clinical Visit Frequencies in Rheumatology: A Systematic Literature Review

2026-11-04T22:50:06.138Z

Research article · Arthritis Care Res (Hoboken), 2023. Average annual visit frequencies: Rheumatoid arthritis (RA), US rheumatologists 5.25

Frequency and Clinical Utility of Antibodies to Extractable Nuclear Antigen in the Setting of a Negative Antinuclear Antibody Test

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2023. New AARD diagnosed 17 of 279 patients

How Does Job Insecurity and Workplace Activity Limitations Relate to Rheumatic Disease Symptom Trajectories in Young Adulthood? A Longitudinal Study

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2022. Association with high persistent symptom trajectory group: Greater workplace activity limitations, high persistent severe pain: RR 1.02 (1.01, 1.03) (95% CI)

Sleep Disturbance and SARS–CoV‐2 Vaccinations in Patients With Chronic Inflammatory Disease

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2023. PROMIS-29 T scores, overall cohort: Sleep disturbance improved following both vaccine doses

Different COVID-19 outcomes among systemic rheumatic diseases: a nation-wide cohort study

2026-11-04T22:45:44.055Z

Cohort study · Rheumatology (Oxford), 2022. RA vs General population: IRR (hospitalization) 1.71 (CI 1.50-1.95)

Physical activity assessment with wearable devices in rheumatic diseases: a systematic review and meta-analysis

2026-11-04T22:45:44.055Z

Meta-analysis · Rheumatology (Oxford), 2022. Difference from recommended PA threshold: MVPA: recommended PA threshold reached 36.35 (95% CI 29.39, 43.31)

Sexual dysfunction in women with systemic autoimmune rheumatic disorders: a systematic review and meta-analysis

2026-11-04T22:45:44.055Z

Meta-analysis · Rheumatology (Oxford), 2022. Overall SD prevalence 63% (95% CI: 56, 69%, I2 = 94%)